[ad_1]
American drugmaker Pfizer and German biotech company BioNTech may generate nearly $ 13bn (£ 9.8bn) in global sales of its coronavirus vaccine next year, which will be split evenly between the two companies, according to analysts. from the US investment bank. Morgan Stanley.
Half of Pfizer would be more than the US pharmaceutical group’s best-selling product, a pneumonia vaccine that generated $ 5.8 billion last year.
Pfizer has agreed to supply 100 million doses to the US at a price of $ 39 for a course of two injections, or $ 19.50 per dose, with the option to supply another 500 million doses under new terms. The EU has asked for doses of 200 million, while the United Kingdom has requested 40 million.
While other vaccine manufacturers have vowed not to benefit from its blows during the pandemic, Pfizer has taken a different stance. Treating it as a business opportunity, the company turned down research funding from the US government under its Operation Warp Speed vaccine program, and used nearly $ 2 billion of its own money to develop the Covid vaccine. -19 with BioNTech from Germany.
However, Mainz-based BioNTech received 375 million euros (335 million pounds) from the German government and a 100 million euro loan from the European Investment Bank. BioNTech is small compared to Pfizer, with revenue of € 109 million last year compared to Pfizer’s $ 52 billion.
The global anti-poverty charity Oxfam said the vaccine would be “zero percent effective for people who cannot access or pay for it,” and urged companies to share their vaccine with other developers.
Rival US drugmaker Johnson & Johnson, along with AstraZeneca, which is developing a coronavirus vaccine in partnership with the University of Oxford, have committed to making their vaccines available on a non-profit basis during this pandemic. AstraZeneca, which is charging governments $ 3 to $ 5 per dose, also said last week that low-income countries would receive their vaccine on a cost basis “in perpetuity.”
The losing US biotech company Moderna, which has received nearly $ 1 billion in research funding from the US government, has priced its vaccine at $ 32- $ 37 per injection.
